Why Innovent Biologics’ tri-specific IBI3055 matters in the race to deplete both B cells and plasma cells
Innovent Biologics unveiled preclinical IBI3055 data in autoimmune disease. Read what this could change for immune-reset therapies.
Can Calidi Biotherapeutics, Inc.’s RedTail platform solve the solid tumor T-cell engager problem?
Calidi Biotherapeutics, Inc. unveils new RedTail and TROP-2 data at AACR 2026. Read what this means for solid tumor immunotherapy and CLD-401 next.
J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results
FDA approves J&J’s teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.